Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.

Updated results of the NCCTG N9831 study demonstrated a strong trend for an absolute benefit in DFS of 4.4% at 5 years with concomitant trastuzumab relative to sequential administration ( P = 0.019).

also in 5,725 other papers

But curiously enough, adjuvant endocrine therapy including tamoxifen and aromatase inhibitors brought about a definite and highly significant decrease in the incidence of contralateral breast cancer for women with estrogen receptor (ER)-positive or ER-unknown disease [2] , [29] – [31] .

also in 132,142 other papers